Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Samantha O Perakis"'
Autor:
Harry J M Groen, Qing Zhou, Ellen Heitzer, Michael R Speicher, Ed Schuuring, Samantha O Perakis, Sabrina Weber, Ricarda Graf, Sabine Hojas, Jakob M Riedl, Armin Gerger, Nadia Dandachi, Marija Balic, Gerald Hoefler, Jochen B Geigl
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Objective Precision oncology depends on translating molecular data into therapy recommendations. However, with the growing complexity of next-generation sequencing-based tests, clinical interpretation of somatic genomic mutations has evolved into a f
Externí odkaz:
https://doaj.org/article/98ddadfdad874cbf99c15c5ec5afd03d
Publikováno v:
Advances in experimental medicine and biology. 937
Colorectal cancer (CRC) is a heterogeneous disease and current treatment options for patients are associated with a wide range of outcomes and tumor responses. Although the traditional TNM staging system continues to serve as a crucial tool for estim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6c96f4dc36264822a219df2ac0049aac
https://pubmed.ncbi.nlm.nih.gov/27573901
https://pubmed.ncbi.nlm.nih.gov/27573901
Autor:
Qing Zhou, Samantha O. Perakis, Peter Ulz, Sumitra Mohan, Jakob M. Riedl, Emina Talakic, Sigurd Lax, Martin Tötsch, Gerald Hoefler, Thomas Bauernhofer, Martin Pichler, Armin Gerger, Jochen B. Geigl, Ellen Heitzer, Michael R. Speicher
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-17 (2020)
Abstract Background Bevacizumab, a monoclonal antibody against soluble VEGFA, is an approved and commonly administered anti-angiogenic drug in patients with metastasized colorectal cancer (mCRC). The survival benefit of anti-VEGF therapy in mCRC pati
Externí odkaz:
https://doaj.org/article/fc254d7ec85e448b9fbac1d663e3b0b7